Pharmaceutical & Medical Device Risk-Sharing & Value-Based Pricing and Reimbursement Schemes

23-24 April 2009, Brussels, Belgium.
There is clearly an increasing need for more innovative pricing and reimbursement agreements to help to balance the (often) conflicting objectives of pharmaceutical and medical technology manufacturers, payers, health technology assessors (HTA), physicians and patients.

There is a sustained increase in the cost of healthcare and ever-increasing range of expensive drugs and technologies available as potential therapies. Clearly, difficult choices need to be made by HTAs about which products receive funding from increasingly restricted healthcare budgets, especially with often insufficient clinical and real-life evidence available.

In terms of innovative agreements, risk-sharing and value-based schemes (for example) are being proposed more often by more manufacturers, in more countries. Such agreements are increasingly being seen as a method in which pharma and medical device companies can obtain HTA approval to finance the drug from limited budgets, but also a strategy to gain a competitive advantage and preferential market access.

Both life sciences companies and policy-makers are looking to achieve a clearer picture of how risk-sharing and value-based agreements can and do work effectively in the real-world. Many complex agreements exist in various countries, whilst some governments and pharma companies in other markets may alternatively have less experience with such schemes.

Many stakeholders need answers to important questions such as: "What is the definition of risk-sharing and value-based pricing schemes? Are such schemes necessary? What are the alternatives? What successful models exist? How can clear endpoints and goals be defined? How can we measure performance effectively? And how different schemes are being viewed by different stakeholders? Can risk-sharing and value-based agreements bring a competitive advantage to pharma companies?"

Why Attend?

  • Benchmark, network and co-operate with policy makers and key, influential figures. Get the best and most focused picture of risk-sharing and value-based pricing models today.
  • Understand what are the most up to date, innovative agreement solutions and future trends in different countries globally.
  • Find out if risk-sharing and value-based pricing schemes can help pharma and medical device manufacturers achieve preferential market access and a competitive advantage.
  • Learn how drug effectiveness, value and safety is being demonstrated in different regions, in real-life.
  • Understand the best ways to communicate value with stakeholders and achieve maximum patient and market access.
  • Hear the perspectives of all stakeholder groups: Ministries of Health, HTA Agencies, Insurers, Doctors, Patients and patient groups, Health economists and the Pharmaceutical Industry.
  • Discover how payers are evaluating a range of complex pricing and reimbursement agreements.
  • Understand what patients want and what they define as a quality treatment, that enhances their lives.

Who Should Attend?
Pharmaceutical companies, Vice-Presidents, Directors, Managers involved in:
Pricing & Reimbursement, Health Economics & Outcomes, Government & Stakeholder Relations, Regulatory Affairs, Medical Affairs, Marketing, Therapy Area Heads, Market Access, Country Managers

Solution providers consultants:
CEOs, Business Development, Senior Consultants, Regional Heads

Independent Academics, Health Economists, Senior Doctors, & Patient Representatives.

For further information and registration, please visit:
http://www.nextlevelpharma.com/events/view/22

About NextLevel Pharma
NextLevel Pharma is a leading, global strategic business information and opportunity provider for the international life sciences industry.

NextLevel Pharma brings the life sciences industry closer together and organise intelligent conferences and events for industry, personalised meetings for individual companies, as well as tailored partnering services.

For more information, please visit www.nextlevelpharma.com.

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...